CV Ranexa Testicular Safety Issue Resolved, Firm Says; QT Issue “Receding”
Executive Summary
CV Therapeutics believes that it can resolve FDA's questions about potential testicular toxicity associated with the pending chronic angina therapy Ranexa (ranolazine) in the "short term.